Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06659744 · ClinicalTrials.gov registry record
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims
A clinical trial of Diabetes Mellitus, Type 2, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 158,310
- Enrollment target
- 1
- Study location
NCT06659744: Completed study of Diabetes Mellitus, Type 2, sponsored by Brigham and Women's Hospital.
NCT06659744 is a study of Diabetes Mellitus, Type 2 that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 158,310 participants, above the 4,030-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (3828% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06659744, a study of Diabetes Mellitus, Type 2, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 158,310 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Hazard ratio
Conditions Studied
Interventions
- DRUG New use of semaglutide injection
- DRUG New initiation of sitagliptin
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158,310 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2025-03-06 |
What the finished NCT06659744 record still lists
NCT06659744 is an observational study that tracks outcomes without assigning an intervention. Its 158,310 participants enrollment target places it among the larger protocols in the corpus, above the 4,030-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (3828% higher).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which New use of semaglutide injection is the first listed.
NCT06659744 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06659744 about?
NCT06659744 is a clinical study titled "Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT06659744?
This trial is currently completed. The enrollment target is 158,310 participants. The study started on 2024-10-24. Estimated completion is 2025-03-06.
What conditions does trial NCT06659744 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT06659744?
The interventions under investigation include: New use of semaglutide injection (DRUG), New initiation of sitagliptin (DRUG).
Who is sponsoring clinical trial NCT06659744?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06659744 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06659744's enrollment target sits among peer trials
158,310 3rd of 348 higher than 346 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI